PTPN1 and neoplasm: As loss of either PTPN2 or PTPN1 increased the sensitivity of tumour cells to checkpoint blockade in an in vivo CRISPR screen, and because both phosphatases dampen immune cell activation3–6,11, we sought to identify a dual PTPN2/N1 inhibitor to further enhance anti-tumour activity.